102 results
Page 2 of 6
8-K
EX-10.1
zwfm7i 3mg7l7fo
14 Aug 23
Entry into a Material Definitive Agreement
7:29am
8-K
1dysp
22 Jun 23
Departure of Directors or Certain Officers
5:12pm
8-K
o2h24
6 Jun 23
Departure of Directors or Certain Officers
4:02pm
144
mhhjub
1 Jun 23
Notice of proposed sale of securities
9:25pm
144
s6kq1n
1 Jun 23
Notice of proposed sale of securities
9:24pm
8-K
eney2ap zl6tm
27 Apr 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:07pm
PRE 14A
2omr3xtht8u
27 Apr 23
Preliminary proxy
4:03pm
10-K/A
m43rdxe7yjmb3c0r
27 Apr 23
Annual report (amended)
4:02pm
8-K
EX-99.1
hqfkk9k
8 Nov 22
Taysha Gene Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
7:06am
8-K/A
EX-10.2
tx0oc9wevqgnfok1j
31 Oct 22
Entry into a Material Definitive Agreement
8:45am
8-K/A
EX-10.1
wxxyd
31 Oct 22
Entry into a Material Definitive Agreement
8:45am
8-K
EX-1.1
xgxbc3evmc mzlkw
27 Oct 22
Taysha Announces Pricing of Public Offering of Common Stock
5:18pm
424B5
9ogk qir60qq
27 Oct 22
Prospectus supplement for primary offering
5:13pm
424B5
btt9zv8j wt7hoz5u2t
25 Oct 22
Prospectus supplement for primary offering
4:35pm